

**AUTHOR INDEX  
VOLUME 8 NO. 1 YEAR 2024****A**

Acep Tantan H. 35  
Agus Budi Maryoto 7  
Agus Cakrahaya 7  
Ana Islamiyah Syamila 56, 57, 58,  
59, 60, 61, 62, 63, 64, 65, 66,  
67  
Andriyanto 7  
Anita Dewi Prahastuti Sujoso 56  
Annisa Auliya Rahman 1  
Asep lin Nur Indra 35, 40  
Aulia Chairani 7  
Ayu Yuliana F. 20

**B**

Bagus Muhammad Ihsan 42, 43,  
44, 45, 46, 47  
Belgis 1

**C**

Cecep Dani Sucipto 42  
Celine Catharina R. 20  
Conny Riana Tjampakasari 68

**E**

Erlinda Widyastuti 1  
Eunike Serfina F. 20

**F**

Fusvita Merdekawati 35, 40

**I**

Ida Chairanna Mahirawatie 48, 49,  
50, 51, 52, 53, 54, 55  
I Gusti Ayu Kusuma Astuti Ngurah  
Putri 48

**K**

Khayan 42, 46

**L**

Lina Choridah 20  
Linda Triana 42  
Lis Widodo Peni 13, 14, 15, 16, 17,  
18, 19

**M**

Merry Amnesti 20

**N**

Ninie Hardini 7  
Nisa'ur Rosyidah 1  
Noeroel Widajati 28  
Nur Septia Handayani 1

**P**

Pilar Menara Falah 13  
Pritha Maya Savitri 7

**R**

Ragil Ismi Hartanti 56  
Reny Indrayani 56  
Revina Dewi S. 20

**S**

Saikhunuddin 28, 29, 30, 31, 32,  
33, 34  
Samsul A. 7  
Siti Masrochah 20  
Siti Nuristiqomah Fajri 35, 36, 37,  
38, 39, 40, 41

**T**

Tati Febrianti 68, 69, 70, 71, 72, 73,  
74, 75, 76, 77

**W**

Wahdaniah 42  
Widyana Lakshmi Puspita 42

**Y**

Yaya Kardiana 7  
Yudha Nurdian 13

**Z**

Zakiah Nada Nuralfilail 7, 8, 9, 10,  
11, 12



## SUBJECT INDEX VOLUME 8 NO. 1 YEAR 2024

### A

AMP 72  
Anesthesia 15  
Antimicrobial Peptide (AMP) 72

### B

*Bacillus* 72, 73, 76  
*Bacillus* sp. TL12 73  
Bacteriocins 68, 72, 73, 74, 76, 77  
Bilateral Ovariectomy (BOVX) 14  
Body Mass Index (BMI) 7, 8, 9, 10, 12  
BOVX 14, 15, 17  
Brain 12, 18, 20, 23, 26, 27  
*Brugia malayi* 43, 45  
*Brugia timori* 43

### C

CA-MRSA 69, 70  
Caries 48, 49, 54  
Chi-square test 8, 28, 32  
Cho 20, 21, 22, 24, 25, 26, 34  
Community Acquired Infections-Methicillin Resistant *Staphylococcus aureus* (CA-MRSA) 69  
Concentration 35, 38, 70  
Coventional polymerase chain reaction 42  
COVID 19 56, 57, 58, 63, 66  
Cr 20, 21, 22, 24, 25  
Creatine (Cr) 20, 24  
Cycle Threshold (CT) 44

### D

Dehydroepiandrosterone (DHEA) 13, 14, 15, 17, 18, 19  
Dental health 48, 49, 50, 52  
Deoxyribonucleic acid (DNA) 6, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47

Diabetic Foot Infection (DFI) 70, 73, 75  
Diffusing Capacity of The Lungs for Carbon Monoxide (DLCO) 10  
Dysplasia 2

### E

*E. coli* 37, 72, 73  
*E. coli* BL 21(DE3)/pET15b 73  
Electrophoresis 35, 36, 40, 44  
Empowerment 48  
Enhancement 13, 15  
*Enterocin* AS - 48 75  
*Enterococcus* 72, 73, 74, 75, 76  
*Enterococcus faecalis* 74, 75  
*Enterococcus aecalis* UGRA10 73  
*Enterococcus faecalis* UGRA10 75  
Enzim transaminase 1  
EPS 71  
Epulis gravidarum 48, 49  
*Escherichia coli* 35, 36, 40  
EtBr 35, 36, 37, 39  
Ethidium bromide (EtBr) 35, 36  
Extracellular Polymeric Substance (EPS) 71

### F

Fatigue 12, 28  
Filariasis 42, 43, 46, 47  
Fisher test 9  
Forced Ekspiratory Volume (FEP) 10

### G

Geneaid Kit 36  
Gingivitis gravidarum 48, 49  
Glycerin 15  
Gram-negative 68, 70, 72, 75  
Gram-positive 68, 70, 72, 75

### H

HA-MRSA 69  
Harris hematoxylin 35, 36, 37, 38, 39, 40  
HBsAg 1, 2, 3, 4, 5, 6  
Heart failure 2  
Hematoxylin 15, 35, 36, 39, 40, 41  
Hemoglobin 8, 10  
Hepatitis B 1, 2, 5, 6  
Hepatitis B surface antigen (HBsAg) 1  
High-Resolution Melting (HRM) 43  
Hormone Replacement Therapy (HRT) 17, 19  
Hospital Associated-Methicillin Resistant *Staphylococcus aureus* (HA-MRSA) 69  
HRM 42, 43, 45, 47  
Hypobaric chamber 7, 8, 10, 11  
Hypoxia 8, 11, 12

### I

Fibrinogen-Binding Surface Protein (FnPBP) 75  
IFRC 28, 29  
ImageJ 35, 37, 38, 39, 40, 41  
Immunoactive 2  
Immunotolerance 2  
Indeks Massa Tubuh (IMT) 7, 12  
Industrial Fatigue Research Committee (IFRC) 28  
Iron-Responsive Surface determinant (IsdB) 75  
IsdB 75

### K

Kendall's tau 1, 2, 3, 4

### L

*Lactococcus* 72, 73, 74  
*Lactococcus garviae* 73  
*Lactococcus garviae* KS 1546 73

*Lactococcus lactis* 73, 74  
Lesion area 22  
Lipids Lactate (LL) 20, 21, 22, 24, 25, 26  
Lysostaphin Nano-Emulgel (LNEG) 75

## M

Menopausal Vaginal Changes (REVIVE) 14  
Menopause 14, 18, 19  
Metabolite 20  
Metastatic carcinoma 2  
*Methicillin-Resistant Staphylococcus aureus* (MRSA) 68, 69, 70, 71, 72, 73, 75, 77  
Microfilariae 42  
MRSA 68, 69, 70, 71, 72, 73, 74, 75, 76, 77  
MRSA biofilms 68, 69, 72, 73, 74, 75, 76  
MR spectroscopy 20  
Muscle 2, 13, 14, 15, 16, 17  
Myo-Inositol (MI) 20, 21, 22, 24, 25, 26

## N

NAA N-Acetyl Aspartate (NAA) 20, 21, 22, 23, 24, 25, 26  
Neutral Buffered Formalin (NBF) 15  
Normality test 22

## O

Occupational Health and Safety (OHS) 56, 58, 59, 60, 62, 63, 66  
Occupational Safety and Health (OSH) 9  
OHS practices 56, 59, 66  
Olysaccharide Intercellular Adhes (PIA) 71  
One-sample kolmogorov smirnov test 22  
Oral health literacy 48, 50, 54  
Ovariectomy 13, 14, 17, 18, 19  
Ovaries 14, 15

## P

*Paenibacillus* 72, 74  
Paired samples T test 51  
Paired T test 20, 22, 24, 25

PCR 36, 37, 40, 42, 43, 44, 45, 46, 47  
PCR konvensional 42  
PCR microtubes 37  
PCR thermal 36, 37  
PCR tool 43, 44  
Perilesional area 22  
periodontitis 48, 49  
Personal Protective Equipment (PPE) 64  
Pittsburgh Sleep Quality Index questionnaire (PSQI) 28  
PMW 14, 17  
Polymerase Chain Reaction (PCR) 36, 42, 43, 44, 45, 46, 47  
Post-Menopausal Women (PMW) 14  
PPE 63, 64  
Pregnancy 48, 49, 55  
Pregnant women 48, 49, 51, 54  
progesterone 17  
Promega Kit 37  
Protozoa 71  
PSQI 28, 29, 34  
Pulmonary ventilation response 8

## Q

qPCR 42, 43, 44, 45, 46  
qPCR-HRM 42, 43, 45  
Quantitative PCR High-Resolution Melting (qPCR-HRM) 42

## R

Ready View software 21, 22  
Residual 2, 21  
Resistance 68  
Rest time 30, 31, 32, 33  
REVIVE 14, 19  
rRNA 35, 37

## S

SARS-CoV-2 57  
*S. aureus* 69, 70, 73, 74  
SCCmec 70  
SD 15, 16, 37, 50, 55  
SdrC 75  
SensiFAST HRM Kit reagent 43  
Serine Aspartate Repeat Protein (SdrC) 75  
Serum Glutamic Oxaloacetate Transaminase (SGOT) 1, 2

Serum Glutamic Pyruvic Transaminase (SGPT) 1, 2  
SGOT 1, 2, 3, 4, 5, 6  
SGPT 1, 2, 3, 4, 5, 6  
Shift direction 33  
Shift rotation 29, 32  
Shift type 33  
Shift work 28, 29, 31  
Skeletal 2  
Sleep quality 28, 29, 31  
Soaking time 35  
Software READY View 20  
Spearman 2  
SSRT 28, 29  
Standard Deviations (SD) 37  
Staphylococcal Cassette Chromosome mec (SCCmec) 70  
*Staphylococcus aureus* 68, 69, 70, 71, 72, 73, 75, 76, 77  
Subjective Self-Rating Test (SSRT) 28

## T

TE 20, 21, 22, 23, 24, 25, 26, 27  
Temperature Melting (TM) 44, 45  
Testosterone 17  
Time echo 20  
Time Echo (TE) 20, 21  
Time of Useful Consciousness (TUC) 7, 8, 9, 10, 11  
Transaminase enzymes 1, 2  
Tris-Acetate EDTA (TAE) 36, 37  
Tris-Borate (TBE) 36  
Tris-Phosphate (TPE) 36

## U

Urinary Tract Infections (UTIs) 14  
Uterus 14

## V

Vaginal wall 13  
Vancomycin-Resistant *S. aureus* (VRSA) 70  
Voxel measurement 22, 24, 25

## W

Waktu Sadar Efektif (WSE) 7  
*W. bancrofti* 44, 45, 46  
Working period 29, 30  
Workplaces 56, 59  
*Wuchereria bancrofti* 42, 43, 44, 47



# Journal of Vocational Health Studies

www.e-journal.unair.ac.id/JVHS

## GUIDELINES FOR WRITERS

The **Journal of Vocational Health Studies** only accepts original manuscripts that have never been published. Manuscripts can be in the form of **Original Research Articles, Literature Reviews, and Case Studies** which are innovative thinking concepts that are useful for supporting the progress of science, education, and practice, especially in the vocational field. Manuscripts should be written in English in an effective and academic style using the Harvard style system.

### TYPE OF ARTICLE

The Journal of Vocational Health Studies accepts and publishes articles in the form of **Original Research Articles, Literature Reviews, and Case Studies**.

1. **An Original Research Article** is a complete study of research activity or part of research with a complete topic study, containing research or observations that meet scientific principles including adequate experimental design and statistical analysis. The study must fulfill the bioethical aspects of research. Epidemiological studies and data studies over the past period are included in the research manuscript category, so they must comply with scientific principles and adequate statistical analysis
2. **A Literature Review** is a comprehensive literature review, critical-analytical in nature, which provides current information on a topic or contains future views regarding an issue. Literature studies must provide complete information from previous research in the form of existing facts or data, convey the author's analysis and critical study of the collection of facts or data, and conclude it into an acceptable view or something that should be used for development in the future. Literature studies that are instructional in a particular topic may still be accepted if deemed.
3. **A Case Study** is a report of an event or case in the clinical, pathological, or other fields that is deemed necessary to be published but is not sufficient to be written in the form of a research manuscript. Case study manuscripts that provide new information or that can contribute to existing literature are preferred

### GENERAL WRITING INSTRUCTIONS

1. Manuscripts sent to the editor are manuscripts that have never been published in other scientific journals (in print or online or are not being sent to other journals).
2. The manuscript should be written in English, clear, straightforward, and concise.
3. The manuscript was typed using the MS. Word program, with A4 size paper. The font used must be Times New Roman, 14 pt for the title and 12 pt for the body of the text. Headlines are typed in bold, while Latin names are typed in italics. Manuscripts are typed using 1.5 cm spacing with left, right, top, and bottom margins of 2.5 cm. **The length of the manuscript should not be below 8 pages and does not exceed 12 pages.**

**The research manuscript has a systematic structure as follows:**

**The title page** contains **the title written in Indonesian and English**, the author's name (written in full without title), the author's affiliation, and a short title (running title). **The title should be no more than 14 words and the short title should be no more 6 words.** The author's affiliation is written in full with department or laboratory accompanied by institution/university along with postal code. If there is more than one author, with different agency addresses, then each name is given an index in Arabic numerals. At the bottom of the title page is the identity of the correspondence writer (responsible for correspondence) including name and address completed with telephone number, cellphone, fax, and email.

**The abstract** is written in **English and Indonesian**, no more than 250 words, and is the essence of the entire article, including background, objectives, methods, results, and conclusions. The abstract is equipped with **keywords arranged alphabetically with 3-5 keywords.**

**The introduction** is written concisely and contains the background, supporting literature, problem statement, research objectives, and benefits of the research.

**The material and method** contain an explanation of the materials and tools used, time, place, techniques, and research design. The method must be explained as completely as possible so that other researchers can carry out repeated trials. References are given to little-known methods. The source or reference for the material or product used is stated (name of company and country, may be accompanied by catalog number). The inclusion of a commercial name must be accompanied by the generic name.

**The result** are stated clearly. If necessary, complete with tables, illustrations (pictures, graphs, diagrams), or photos. Results expressed in tables or illustrations do not need to be explained at length in the text. **Tables** are numbered and referred to sequentially in the text, and titles are written briefly and clearly. Information is placed in footnotes, not in the title. Please explain all abbreviations in the footnotes. Vertical lines on the table are kept to a minimum, to make things clearer. **Decimal numbers** are marked with a dot for English. **Illustrations**, which can be in the form of pictures, graphs, or diagrams, are numbered and referred to sequentially in the text. Information is given briefly and clearly below the illustration (not in the illustration). **Color photos** must be contrasting, sharp, and clear. The smallest size is 125×195 mm.

**The discussion** is written separately from the results. The discussion is not a repetition of the narrative of the results, but is an interpretation and analysis of the data obtained, either by referring to, comparing, strengthening, or criticizing the results of previous research. The discussion explains the research results, how the reported research results can solve the problem, differences and similarities with previous research, and possible developments.

**The conclusion** is written briefly in a separate paragraph at the end of the discussion and is not a separate subtitle

**The acknowledgments** are to individuals or institutions who have made important contributions to the implementation of the research (funders, data source providers, research materials, research facilities, and others), but who are not part of the writing team. At the end the author must include a statement regarding the

absence of a conflict of interest as follows: **“The author declares that there is no conflict of interest with the parties involved in this research.”**

**The reference** contain all published articles referred to in the manuscript. Standard reference using “Elsevier - Harvard 2”. Author names are arranged alphabetically. The references are minimally 25 from the last 10 years before the date of submission. The way to reference literature in a manuscript is as follows:

#### **Reference format from journal articles:**

Chopade, V.V., Phatak, A.A., Upaganlawar, A.B., Tankar, A.A. 2008. Green tea (*Camellia sinensis*): Chemistry, Traditional, Medicinal Uses and Its Pharmacological Activities - A Review. *Journal of Medicinal Plants Research* Vol. 4(19). Pp. 157–162.

#### **Reference format from textbooks:**

Singh, G. 2007. *Textbook of Orthodontics*. 2<sup>nd</sup> ed. New Delhi: Jaypee Brothers Medical Publishers (P) LTD. Pp. 387–409.

#### **Reference format from proceedings:**

Perry, C.H., Lu, F., Namavar, F., Kalkhoran, N.M., Soreff, R.A. 1991. Radical styloid. *Proceedings of the 10<sup>th</sup> International Congress of Clinic*; New York, USA.

Favier, J.J., Camel, D. 1986. Enforcement of Data in Medical information. In: Lun KL, editor. *Proceedings of The Eight International Conference on Medicine*; York, UK.

#### **Reference format from thesis or dissertation:**

Ramos, R. 1992. *Preventive Health Amendments*. PhD Thesis. College van Dekanen. University of Twente. The Netherlands.

Salim, S. 1995. Pengaruh Humiditas dan Waktu Penyimpanan serta Cara Curing terhadap Sifat Fisik, Kimia dan Mekanik Akrilik Basis Gigi Tiruan. *Disertasi*. Surabaya: Pascasarjana Universitas Airlangga.

#### **Reference format from translation book:**

Amerongen, A.V.N., Michels, L.F.E., Roukema, P.A., Veerman, E.C.I. 1986. *Ludah dan Kelenjar Ludah Arti bagi Kesehatan Gigi*. Rafiah Arbyono dan Sutatmi Suryo. Yogyakarta: Gadjah Mada University Press. Pp. 1–42.

#### **Reference format from the internet:**

Fernanda, A.R. 2015. Hubungan Kualitas Pelayanan terhadap Kepuasan Konsumen di Laboratorium Prodia Bandung. Available from: <http://repository.widyatama.ac.id/xmlui/handle/123456789/2754>. Diakses: 17 February 2015.

Yu, F. 1997. Management of Thumbs Duplication. *Emerg Infect Dis* (on line) <http://www.cdc.gov/ncidod/EID/eid.html>.

Koo, D.J., Chitwoode, D.D., Sanchez, J. 2008. Violent Victimization and The Routine activities/lifestyle of Active Drug Users. *Journal of Drug Issues* 2008; 38: 1105-37. Retrieved from <http://www2.criminology.fsu.edu/~jdi/>

### **Instructions for writing Literature Review**

**Literature Review** manuscripts are arranged systematically as follows: title, author's name, abstract, introduction, literature review, discussion, conclusion (and suggestions if any), and references.

### **Instructions for writing Case Study**

**Case Study** manuscripts are arranged systematically as follows: title, author's name, abstract, introduction, case analysis (accompanied by photos), discussion, conclusions (and suggestions if any), and references.

1. **Tables and figures** are placed on one page accompanied by titles and descriptions. The graph comes with a separate original file in MS. Excel format. Images containing photos must attach original, high-resolution photos in JPEG format. Authors can also include photos that will be proposed as the front page (cover) of the journal.
2. Manuscripts can be sent via email: [jvhs@journal.unair.ac.id](mailto:jvhs@journal.unair.ac.id). Submitted manuscripts are accompanied by a *Copyright Transfer Agreement* (CTA), Author Statement which can be seen in the journal template as well as other certificates deemed necessary (for example: Letter of approval from the ethics commission, research permit, permission to take research samples, *Material Transfer Agreement* (MTA), and others).

3. When the manuscript has been received by the editor, the author will receive a "notice to be processed" no later than 7 days after the manuscript is received
4. Every article sent to the editorial office of the Journal of Vocational Health Studies is free of charge (free - no page charge) including free article processing fees. The publication costs are borne by the publisher of this journal.

### **Send manuscript to:**

Ratna Wahyuni, S.Si., M.Kes. Ph.D.  
Editorial Journal of Vocational Health Studies  
Department of Health, Faculty of Vocational Studies,  
Universitas Airlangga  
Jl. Dharmawangsa Dalam No. 28-32, Surabaya, 60286  
Jawa Timur - Indonesia  
Telp: 031-5033869, 031-5053156 Faks: 031-5053156  
HP: 085233046706  
Email: [jvhs@journal.unair.ac.id](mailto:jvhs@journal.unair.ac.id)